Featured Publications
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis
Farhat L, Behling E, Landeros-Weisenberger A, Levine J, Macul Ferreira de Barros P, Wang Z, Bloch M. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. The Lancet Child & Adolescent Health 2022, 7: 112-126. PMID: 36528030, DOI: 10.1016/s2352-4642(22)00316-9.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychotic drugsMedication categoriesAntipsychotic drugsModerate certaintyIndividual medicationsTourette syndromePharmacological interventionsLow certaintyWHO International Clinical Trials Registry PlatformInternational Clinical Trials Registry PlatformSystematic reviewClinical Trials Registry PlatformChoice of medicationCochrane Central RegisterNetwork meta-analysis frameworkTrials Registry PlatformRandom-effects networkTerms of tolerabilityCertainty of evidenceClinical practice guidelinesComorbid attention deficit hyperactivity disorderStandardised mean differenceTreatment of childrenAttention deficit hyperactivity disorderWeb of ScienceEfficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal Of Psychiatry 2021, 178: 352-362. PMID: 33653121, DOI: 10.1176/appi.ajp.2020.20010018.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusionThe Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Sanacora G. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. American Journal Of Psychiatry 2017, 175: 150-158. PMID: 28969441, PMCID: PMC5794524, DOI: 10.1176/appi.ajp.2017.17040472.Peer-Reviewed Original ResearchConceptsIndividual participant dataLong-term safetySuicidal ideationKetamine effectsSingle doseParticipant dataSuicide itemOutcome measuresSystematic reviewIndividual Participant Data Meta-AnalysisLimited treatment optionsPrimary outcome measureSelf-reported outcome measuresData Meta-AnalysisIntravenous ketaminePublic health crisisKetamine administrationTreatment optionsQIDS-SRDepressed patientsDepressive symptomsIntervention studiesKetamineMeta-AnalysisSuicidal thoughtsMeta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder
Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry 2009, 15: 850-855. PMID: 19468281, PMCID: PMC2888928, DOI: 10.1038/mp.2009.50.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsY-BOCS scoresSerotonin reuptake inhibitorsObsessive-compulsive disorderHigh dosesReuptake inhibitorsTreatment respondersDose of SSRIsTreatment efficacyDouble-blind placebo-controlled clinical trialGreater side effect burdenPlacebo-controlled clinical trialSide effect burdenAbsolute risk differenceTreatment of adultsGreater treatment efficacyMajor depressive disorderImproved treatment efficacyTreatment of OCDDose-response relationshipRevMan 4.2.8Clinical trialsDepressive disorderCause dropoutsMean change
2023
Prevalence and gender distribution of excoriation (skin-picking) disorder: A systematic review and meta-analysis
Farhat L, Reid M, Bloch M, Olfson E. Prevalence and gender distribution of excoriation (skin-picking) disorder: A systematic review and meta-analysis. Journal Of Psychiatric Research 2023, 161: 412-418. PMID: 37023597, PMCID: PMC11137851, DOI: 10.1016/j.jpsychires.2023.03.034.Peer-Reviewed Original ResearchConceptsExcoriation disorderPublic health impactEpidemiological studiesGeneral populationSystematic reviewHealth impactsDifferent prevalence estimatesPooled prevalenceOverall prevalenceInclusion criteriaMale ratioPubMed searchPrevalence estimatesGender distributionDisordersPrevalenceDatabase searchEMBASEReviewPopulationPubMedPsycINFOStudyWomen
2022
Prevalence and gender distribution of trichotillomania: A systematic review and meta-analysis
Thomson HA, Farhat LC, Olfson E, Levine JLS, Bloch MH. Prevalence and gender distribution of trichotillomania: A systematic review and meta-analysis. Journal Of Psychiatric Research 2022, 153: 73-81. PMID: 35802953, DOI: 10.1016/j.jpsychires.2022.06.058.Peer-Reviewed Original ResearchConceptsNoticeable hair lossHair-pulling behaviorOdds ratioHair lossPrevalence estimatesSystematic reviewGender distributionSignificant public health impactMental Disorders criteriaPublic health impactMale odds ratioFemale preponderanceEpidemiological studiesPrevalence dataUnderstudied conditionDisorder criteriaStatistical ManualTrichotillomaniaEpidemiological samplePrevalenceHealth impactsConsiderable heterogeneityDatabase searchAdditional researchFemalesParental age and the risk of bipolar disorder in the offspring: A systematic review and meta‐analysis
Polga N, de Barros P, Farhat LC, de Almeida K, Bloch MH, Lafer B. Parental age and the risk of bipolar disorder in the offspring: A systematic review and meta‐analysis. Acta Psychiatrica Scandinavica 2022, 145: 568-577. PMID: 35188977, DOI: 10.1111/acps.13418.Peer-Reviewed Original ResearchConceptsRisk of BDBipolar disorderMaternal ageOdds ratioParental ageReference categoryOlder maternal age groupsAge groupsPaternal age groupsMaternal age groupsWeb of ScienceObservational studySystematic reviewAgeFurther studiesRiskDisordersOffspringAssociationEffect size indexEMBASEGroupSize indexPubMedStudy
2021
A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome
Bloch MH, Landeros-Weisenberger A, Johnson JA, Leckman JF. A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome. Journal Of Neuropsychiatry 2021, 33: 328-336. PMID: 34340527, DOI: 10.1176/appi.neuropsych.19080178.Peer-Reviewed Original ResearchConceptsTourette syndromeTic symptomsUncontrolled trialsYale Global Tic Severity Scale-Total Tic ScoreDouble-blind placebo-controlled trialAvailable evidence-based treatmentsPhase 2 pilot studyExtension phasePlacebo-controlled trialRefractory Tourette syndromeTotal tic scoreEffective pharmacological treatmentCannabis-derived compoundsEvidence-based treatmentsTHC dosingSecondary outcomesPrimary outcomeComorbid conditionsPharmacological treatmentTic scoreYGTSS scoresTherapeutic combinationsSide effectsTrial designSyndrome
2020
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study
Taylor JH, Appel S, Eli M, Alexander-Bloch A, Maayan L, Gur RE, Bloch MH. Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study. Journal Of Child And Adolescent Psychopharmacology 2020, 31: 46-52. PMID: 32633541, PMCID: PMC7891207, DOI: 10.1089/cap.2020.0030.Peer-Reviewed Original ResearchConceptsClinical Global Impression-ImprovementClinical responseEarly Onset Schizophrenia Spectrum Disorders StudySymptom improvementWeek 8Early-onset schizophrenia spectrum disordersClinical response timeWeeks of treatmentProportional hazards regressionDisorders StudyTime courseSchizophrenia spectrum disordersClinical nonresponseMedication differencesClinical respondersTreatment initiationClinical nonrespondersMedian timeHazards regressionAntipsychotic treatmentEarly improvementSchizoaffective disorderClinical judgmentMore weeksYouth ages 8
2019
N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study
Li F, Welling MC, Johnson JA, Coughlin C, Mulqueen J, Jakubovski E, Coury S, Landeros-Weisenberger A, Bloch MH. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study. Journal Of Child And Adolescent Psychopharmacology 2019, 30: 32-37. PMID: 31800306, PMCID: PMC7133418, DOI: 10.1089/cap.2019.0041.Peer-Reviewed Original ResearchConceptsCY-BOCS total scoreN-acetylcysteineYale-Brown ObsessiveTotal scorePlacebo groupNAC groupStudy populationBenefit of NACPlacebo-controlled clinical trialSymptom severityEffect of NACMild adverse eventsOCD symptom severityLarger study populationPediatric obsessive-compulsive disorderSmall pilot studyChildren's Yale-Brown ObsessiveStudy medicationAdverse eventsPrimary outcomeGlutamate dysfunctionObsessive-compulsive disorderWeek 12Future trialsNAC treatmentThe impact of attention deficit hyperactivity disorder in obsessive‐compulsive disorder subjects
Blanco‐Vieira T, Santos M, Ferrão YA, Torres AR, Miguel EC, Bloch MH, Leckman JF, do Rosario MC. The impact of attention deficit hyperactivity disorder in obsessive‐compulsive disorder subjects. Depression And Anxiety 2019, 36: 533-542. PMID: 30990937, DOI: 10.1002/da.22898.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderAdult OCD patientsObsessive-compulsive disorderDeficit hyperactivity disorderOCD patientsClinical characteristicsExact testFeatures of ADHDHyperactivity disorderSubgroup of patientsAdult obsessive-compulsive disorderComorbid attention deficit hyperactivity disorderSpecific clinical featuresCross-sectional studyObsessive-compulsive disorder (OCD) subjectsLogistic regression analysisFisher's exact testBrazilian Research ConsortiumMann-Whitney testAdult patientsRheumatic feverDevelopment of interventionsClinical featuresObsessive-compulsive spectrum disordersLifetime prevalence
2018
Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study
Taylor JH, Jakubovski E, Gabriel D, Bloch MH. Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study. Journal Of Child And Adolescent Psychopharmacology 2018, 28: 474-484. PMID: 29920116, PMCID: PMC6154761, DOI: 10.1089/cap.2017.0147.Peer-Reviewed Original Research
2017
Monotherapy Insufficient in Severe Anxiety? Predictors and Moderators in the Child/Adolescent Anxiety Multimodal Study
Taylor JH, Lebowitz ER, Jakubovski E, Coughlin CG, Silverman WK, Bloch MH. Monotherapy Insufficient in Severe Anxiety? Predictors and Moderators in the Child/Adolescent Anxiety Multimodal Study. Journal Of Clinical Child & Adolescent Psychology 2017, 47: 266-281. PMID: 28956620, PMCID: PMC6191182, DOI: 10.1080/15374416.2017.1371028.Peer-Reviewed Original ResearchConceptsChild/Adolescent Anxiety Multimodal StudyCognitive behavioral therapyModerators of outcomeSevere anxietyCombination of CBTIndependent evaluator ratingsMultimodal studyParent-rated anxietySeparation anxiety disorderMain effect findingsObsessive-compulsive disorderAnxious youthSocial anxietyChild anxietyBehavioral therapyAnxiety severityPill placeboAnxiety disordersEvaluators' ratingsAnxietyModeratorSocioeconomic statusLow socioeconomic statusYouthEffect findingsKetamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
Taylor JH, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA, Gabriel D, Reed MO, Jakubovski E, Bloch MH. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology 2017, 43: 325-333. PMID: 28849779, PMCID: PMC5729569, DOI: 10.1038/npp.2017.194.Peer-Reviewed Original ResearchConceptsLiebowitz Social Anxiety ScaleSocial anxiety disorderAnxiety disordersSocial Anxiety ScaleSelf-reported anxietySocial phobia symptomsRatings of anxietyPotent N-methyl-d-aspartate receptor antagonistPhobia symptomsAnxiety symptomsAnxiety ScaleImpact of ketamineInitial evidenceAnxietyTreatment respondersVAS anxietyPlacebo-controlled crossover trialRatingsDisordersLinear mixed modelsPrior studiesConcept trialInadequate symptom reliefRandom orderMixed modelsRandomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16Predictors of Long-Term Risky Driving Behavior in the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder
Johnson JA, Jakubovski E, Reed MO, Bloch MH. Predictors of Long-Term Risky Driving Behavior in the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder. Journal Of Child And Adolescent Psychopharmacology 2017, 27: 747-754. PMID: 28771386, PMCID: PMC5651934, DOI: 10.1089/cap.2017.0025.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderRisky driving behaviorsMultimodal Treatment StudyHyperactivity disorderDriving behaviorParental protectivenessLow parental monitoringParental stress levelsTreatment studiesParental stressParental monitoringConduct disorderHigh-risk childrenStepwise logistic regression analysisLogistic regression analysisYears of ageStepwise logistic regressionDiscriminative predictorsHigh-risk behaviorsParental levelIntranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder
Adams TG, Bloch MH, Pittenger C. Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder. Journal Of Clinical Psychopharmacology 2017, 37: 269-271. PMID: 28121735, PMCID: PMC5321820, DOI: 10.1097/jcp.0000000000000659.Peer-Reviewed Original ResearchKetamine as a Treatment for Adolescent Depression: A Case Report
Dwyer JB, Beyer C, Wilkinson ST, Ostroff RB, Qayyum Z, Bloch MH. Ketamine as a Treatment for Adolescent Depression: A Case Report. Journal Of The American Academy Of Child & Adolescent Psychiatry 2017, 56: 352-354. PMID: 28335880, DOI: 10.1016/j.jaac.2017.01.006.Peer-Reviewed Case Reports and Technical NotesPredictors of Long-Term School-Based Behavioral Outcomes in the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder
Reed MO, Jakubovski E, Johnson JA, Bloch MH. Predictors of Long-Term School-Based Behavioral Outcomes in the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder. Journal Of Child And Adolescent Psychopharmacology 2017, 27: 296-309. PMID: 28253029, PMCID: PMC5439457, DOI: 10.1089/cap.2015.0168.Peer-Reviewed Original Research
2016
Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial.
Coughlin CG, Jakubovski E, Bloch MH. Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial. The Journal Of Clinical Psychiatry 2016, 77: e1262-e1269. PMID: 27631142, DOI: 10.4088/jcp.15m10075.Peer-Reviewed Original ResearchConceptsMajor depressive disorderCitalopram treatmentSuicidal ideationClinical predictorsClinical variablesSelective serotonin reuptake inhibitorsNonpsychotic major depressive disorderFirst-line treatmentBaseline clinical variablesSerotonin reuptake inhibitorsWeeks of treatmentSequenced Treatment AlternativesSide effect dataGreater likelihoodTime coursePhase 1Cardiac comorbiditiesNeurologic comorbiditiesBaseline characteristicsSedative medicationsReuptake inhibitorsTrial phase 1Clinical correlatesQuick InventoryDepressive disorder